1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 73, 2022
  5. Article

Annual Review of Medicine

Volume 73, 2022

Fatty Liver Disease: Diagnosis and Stratification

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major public health crisis affecting approximately 25% of the world's population. The spectrum of NAFLD ranges from bland steatosis to steatohepatitis with fibrosis; eventual development of cirrhosis in a subgroup of patients now represents the leading indication for liver transplant in women and in individuals older than 65. The development of noninvasive liver disease assessment tools has led to substantial progress in the diagnosis of NAFLD. Patients with NAFLD are at increased risk of cardiometabolic disease, which should therefore be an important part of the therapeutic approach. This review focuses on diagnosis and risk stratification of NAFLD across the full spectrum of disease, including important considerations in the approach to patients with cirrhosis.

Keyword(s): cirrhosis, fatty liver, NAFLD, NASH, NILDA, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, noninvasive liver disease assessment
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042220-020407
2022-01-27
2024-05-17
Loading full text...

Full text loading...

/deliver/fulltext/med/73/1/annurev-med-042220-020407.html?itemId=/content/journals/10.1146/annurev-med-042220-020407&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Neuschwander-Tetri BA, Caldwell SH. 2003. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37:1202–19
     [Google Scholar]
  2. 2. 
    Byrne CD, Targher G. 2016. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: Is universal screening appropriate?. Diabetologia 59:1141–44
     [Google Scholar]
  3. 3. 
    Estes C, Razavi H, Loomba R et al. 2018. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67:123–33
     [Google Scholar]
  4. 4. 
    Chalasani N, Younossi Z, Lavine JE et al. 2018. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–57
     [Google Scholar]
  5. 5. 
    Wang Z, Zhao X, Chen S et al. 2021. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China. Clin. Gastroenterol. Hepatol. 19:788–96.e4
     [Google Scholar]
  6. 6. 
    Ekstedt M, Hagström H, Nasr P et al. 2015. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:1547–54
     [Google Scholar]
  7. 7. 
    Vilar-Gomez E, Calzadilla-Bertot L, Wong VWS et al. 2018. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 155:443–57.e17
     [Google Scholar]
  8. 8. 
    Hagström H, Nasr P, Ekstedt M et al. 2017. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67:1265–73
     [Google Scholar]
  9. 9. 
    Allen AM, Hicks SB, Mara KC et al. 2019. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity—a longitudinal cohort study. J. Hepatol. 71:1229–36
     [Google Scholar]
  10. 10. 
    Armstrong MJ, Adams LA, Canbay A, Syn WK 2014. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59:1174–97
     [Google Scholar]
  11. 11. 
    Kim D, Choi SY, Park EH et al. 2012. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56:605–13
     [Google Scholar]
  12. 12. 
    Younossi ZM, Blissett D, Blissett R et al. 2016. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64:1577–86
     [Google Scholar]
  13. 13. 
    Kanwal F, Kramer JR, Li L et al. 2020. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology 71:808–19
     [Google Scholar]
  14. 14. 
    Ratziu V, Giral P, Charlotte F et al. 2000. Liver fibrosis in overweight patients. Gastroenterology 118:1117–23
     [Google Scholar]
  15. 15. 
    Angulo P, Keach JC, Batts KP, Lindor KD. 1999. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356–62
     [Google Scholar]
  16. 16. 
    Am. Diabetes Assoc 2019. Standards of medical care in diabetes—2019. Diabetes Care 42:Suppl. 1)
     [Google Scholar]
  17. 17. 
    Noureddin M, Jones C, Alkhouri N et al. 2020. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis. Gastroenterology 159:1985–87.e4
     [Google Scholar]
  18. 18. 
    Shah AG, Lydecker A, Murray K et al. 2009. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7:1104–12
     [Google Scholar]
  19. 19. 
    Davyduke T, Tandon P, Al-Karaghouli M et al. 2019. Impact of implementing a “FIB-4 first” strategy on a pathway for patients with NAFLD referred from primary care. Hepatol. Commun. 3:1322–33
     [Google Scholar]
  20. 20. 
    Srivastava A, Gailer R, Tanwar S et al. 2019. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J. Hepatol. 71:371–78
     [Google Scholar]
  21. 21. 
    Ciardullo S, Muraca E, Perra S et al. 2020. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res. Care 8:e000904
     [Google Scholar]
  22. 22. 
    Papatheodoridi M, Hiriart JB, Lupsor-Platon M et al. 2021. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J. Hepatol. 74:1109–16
     [Google Scholar]
  23. 23. 
    Wang H, Mehal W, Nagy LE, Rotman Y. 2021. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell. Mol. Immunol. 18:73–91
     [Google Scholar]
  24. 24. 
    Tian C, Stokowski RP, Kershenobich D et al. 2010. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 42:21–23
     [Google Scholar]
  25. 25. 
    Ajmera VH, Terrault NA, Harrison SA. 2017. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology 65:2090–99
     [Google Scholar]
  26. 26. 
    Ekstedt M, Franzén LE, Holmqvist M et al. 2009. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 44:366–74
     [Google Scholar]
  27. 27. 
    Mellinger JL, Shedden K, Winder GS et al. 2021. Bariatric surgery and the risk of alcohol-related cirrhosis and alcohol misuse. Liver Int 41:1012–19
     [Google Scholar]
  28. 28. 
    Hines LM, Rimm EB. 2001. Moderate alcohol consumption and coronary heart disease: a review. Postgrad. Med. J. 77:747–52
     [Google Scholar]
  29. 29. 
    Dunn W, Sanyal AJ, Brunt EM et al. 2012. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 57:384–91
     [Google Scholar]
  30. 30. 
    Sookoian S, Pirola CJ. 2016. How safe is moderate alcohol consumption in overweight and obese individuals?. Gastroenterology 150:1698–703.e2
     [Google Scholar]
  31. 31. 
    Ajmera V, Belt P, Wilson LA et al. 2018. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin. Gastroenterol. Hepatol. 16:1511–20.e5
     [Google Scholar]
  32. 32. 
    Åberg F, Helenius-Hietala J, Puukka P et al. 2018. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 67:2141–49
     [Google Scholar]
  33. 33. 
    NIAAA (Natl. Inst. Alcohol Abuse Alcohol.) 2005. Helping patients who drink too much: a clinician's guide Fact Sheet NIAAA Washington, DC: https://pubs.niaaa.nih.gov/publications/practitioner/cliniciansguide2005/guide.pdf
  34. 34. 
    Crabb DW, Im GY, Szabo G et al. 2020. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 71:306–33
     [Google Scholar]
  35. 35. 
    Cabezas J, Lucey MR, Bataller R. 2016. Biomarkers for monitoring alcohol use. Clin. Liver Dis. 8:59–63
     [Google Scholar]
  36. 36. 
    D'Amico G, Pasta L, Morabito A et al. 2014. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment. Pharmacol. Ther. 39:1180–93
     [Google Scholar]
  37. 37. 
    Fede G, D'Amico G, Arvaniti V et al. 2012. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J. Hepatol. 56:810–18
     [Google Scholar]
  38. 38. 
    Moreau R, Jalan R, Gines P et al. 2013. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144:1426–37.e1–9
     [Google Scholar]
  39. 39. 
    O'Leary JG, Reddy KR, Garcia-Tsao G et al. 2018. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology 67:2367–74
     [Google Scholar]
  40. 40. 
    de Franchis R. 2015. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 63:743–52
     [Google Scholar]
  41. 41. 
    Mittal S, El-Serag HB, Sada YH et al. 2016. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 14:124–31.e1
     [Google Scholar]
  42. 42. 
    Loomba R, Lim JK, Patton H, El-Serag HB. 2020. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 158:1822–30
     [Google Scholar]
  43. 43. 
    Fleming KM, Aithal GP, Card TR, West J. 2010. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment. Pharmacol. Ther. 32:1343–50
     [Google Scholar]
  44. 44. 
    D'Amico G, Garcia-Tsao G, Pagliaro L. 2006. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44:217–31
     [Google Scholar]
  45. 45. 
    Sanyal AJ, Harrison SA, Ratziu V et al. 2019. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 70:1913–27
     [Google Scholar]
  46. 46. 
    Harrison SA, Wong VW, Okanoue T et al. 2020. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized Phase III STELLAR trials. J. Hepatol. 73:26–39
     [Google Scholar]
  47. 47. 
    Garcia-Tsao G, Bosch J, Kayali Z et al. 2020. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J. Hepatol. 72:885–95
     [Google Scholar]
  48. 48. 
    Chalasani N, Abdelmalek MF, Garcia-Tsao G et al. 2020. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 158:1334–45.e5
     [Google Scholar]
  49. 49. 
    Bernardi M, Moreau R, Angeli P et al. 2015. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J. Hepatol. 63:1272–84
     [Google Scholar]
  50. 50. 
    Turco L, Garcia-Tsao G, Magnani I et al. 2018. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J. Hepatol. 68:949–58
     [Google Scholar]
  51. 51. 
    Hernaez R, Kramer JR, Liu Y et al. 2019. Prevalence and short-term mortality of acute-on-chronic liver failure: a national cohort study from the USA. J. Hepatol. 70:639–47
     [Google Scholar]
  52. 52. 
    Barr RG, Ferraioli G, Palmeri ML et al. 2015. Elastography assessment of liver fibrosis: Society of Radiologists in Ultrasound consensus conference statement. Radiology 276:845–61
     [Google Scholar]
  53. 53. 
    Cassinotto C, Lapuyade B, Guiu B et al. 2020. Agreement between 2-dimensional shear wave and transient elastography values for diagnosis of advanced chronic liver disease. Clin. Gastroenterol. Hepatol. 18:2971–79.e3
     [Google Scholar]
  54. 54. 
    Thabut D, Bureau C, Layese R et al. 2019. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology 156:997–1009.e5
     [Google Scholar]
  55. 55. 
    Addepally NS, George N, Martinez-Macias R et al. 2018. Hemoglobin A1c has suboptimal performance to diagnose and monitor diabetes mellitus in patients with cirrhosis. Dig. Dis. Sci. 63:3498–508
     [Google Scholar]
  56. 56. 
    EASL (Eur. Assoc. Study Liver) 2010. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 53:397–417
     [Google Scholar]
  57. 57. 
    Ginès P, Solà E, Angeli P et al. 2018. Hepatorenal syndrome. Nat. Rev. Dis. Prim. 4:23
     [Google Scholar]
  58. 58. 
    Serste T, Melot C, Francoz C et al. 2010. Deleterious effects of β-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52:1017–22
     [Google Scholar]
  59. 59. 
    Mandorfer M, Bota S, Schwabl P et al. 2014. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146:1680–90.e1
     [Google Scholar]
  60. 60. 
    Cales P, Bertrais S, Boursier J et al. 2021. Non-selective β-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up. Liver Int 41:168–79
     [Google Scholar]
  61. 61. 
    Facciorusso A, Roy S, Livadas S et al. 2018. Nonselective β-blockers do not affect survival in cirrhotic patients with ascites. Dig. Dis. Sci. 63:1737–46
     [Google Scholar]
  62. 62. 
    Scheiner B, Parada-Rodriguez D, Bucsics T et al. 2017. Non-selective β-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand. J. Gastroenterol. 52:1008–15
     [Google Scholar]
  63. 63. 
    Téllez L, Ibáñez-Samaniego L, Pérez Del Villar C et al. 2020. Non-selective β-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J. Hepatol. 73:1404–14
     [Google Scholar]
  64. 64. 
    Tergast TL, Kimmann M, Laser H et al. 2019. Systemic arterial blood pressure determines the therapeutic window of non-selective β blockers in decompensated cirrhosis. Aliment. Pharmacol. Ther. 50:696–706
     [Google Scholar]
  65. 65. 
    Fried LP, Tangen CM, Walston J et al. 2001. Frailty in older adults: evidence for a phenotype. J. Gerontol. A 56:M146–56
     [Google Scholar]
  66. 66. 
    Duarte-Rojo A, Ruiz-Margáin A, Montaño-Loza AJ et al. 2018. Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list. Liver Transplant 24:122–39
     [Google Scholar]
  67. 67. 
    Lai JC, Sonnenday CJ, Tapper EB et al. 2019. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am. J. Transplant. 19:1896–906
     [Google Scholar]
  68. 68. 
    Saiman Y, Serper M. 2020. Frailty and sarcopenia in patients pre– and post–liver transplant. Clin. Liver Dis. 25:35–51
     [Google Scholar]
  69. 69. 
    Xu C, Mohamad Y, Kappus MR et al. 2021. The relationship between frailty and cirrhosis etiology: from the Functional Assessment in Liver Transplantation (FrAILT) study. Liver Int. 41:2467–73
     [Google Scholar]
  70. 70. 
    Samala N, Desai A, Vilar-Gomez E et al. 2020. Decreased quality of life is significantly associated with body composition in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 18:2980–88.e4
     [Google Scholar]
  71. 71. 
    Aamann L, Ochoa-Sanchez R, Oliveira M et al. 2019. Progressive resistance training prevents loss of muscle mass and strength in bile duct–ligated rats. Liver Int 39:676–83
     [Google Scholar]
  72. 72. 
    Bhanji RA, Narayanan P, Moynagh MR et al. 2019. Differing impact of sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease. Liver Transplant 25:14–24
     [Google Scholar]
  73. 73. 
    Lai JC, Dodge JL, Kappus MR et al. 2020. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J. Hepatol. 73:575–81
     [Google Scholar]
  74. 74. 
    Bunchorntavakul C, Reddy KR. 2020. Malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment. Pharmacol. Ther. 51:64–77
     [Google Scholar]
  75. 75. 
    Carey EJ, Steidley DE, Aqel BA et al. 2010. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transplant 16:1373–78
     [Google Scholar]
  76. 76. 
    Lai JC, Covinsky KE, Dodge JL et al. 2017. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 66:564–74
     [Google Scholar]
  77. 77. 
    Lai JC, Dodge JL, Kappus MR et al. 2020. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J. Hepatol. 73:575–81
     [Google Scholar]
  78. 78. 
    Duarte-Rojo A, Bloomer PM, Rogers RJ et al. 2021. Introducing EL-FIT (Exercise and Liver FITness): a smartphone app to prehabilitate and monitor liver transplant candidates. Liver Transplant 27:502–12
     [Google Scholar]
  79. 79. 
    Cai C, Song X, Chen Y et al. 2020. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatol. Int. 14:115–26
     [Google Scholar]
  80. 80. 
    Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. 2020. Harnessing muscle–liver crosstalk to treat nonalcoholic steatohepatitis. Front. Endocrinol. 11:592373
     [Google Scholar]
  81. 81. 
    Hong HC, Hwang SY, Choi HY et al. 2014. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 59:1772–78
     [Google Scholar]
  82. 82. 
    Prado CM, Cushen SJ, Orsso CE, Ryan AM. 2016. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc. Nutr. Soc. 75:188–98
     [Google Scholar]
  83. 83. 
    Carey EJ, Lai JC, Wang CW et al. 2017. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transplant 23:625–33
     [Google Scholar]
  84. 84. 
    Bhanji RA, Takahashi N, Moynagh MR et al. 2019. The evolution and impact of sarcopenia pre- and post-liver transplantation. Aliment. Pharmacol. Ther. 49:807–13
     [Google Scholar]
  85. 85. 
    Kim G, Lee SE, Lee YB et al. 2018. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology 68:1755–68
     [Google Scholar]
  86. 86. 
    Lee MJ, Kim EH, Bae SJ et al. 2019. Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease: a 10-year retrospective cohort study. Gut Liver 13:67–76
     [Google Scholar]
  87. 87. 
    Kilic MK, Kizilarslanoglu MC, Arik G et al. 2017. Association of bioelectrical impedance analysis–derived phase angle and sarcopenia in older adults. Nutr. Clin. Pract. 32:103–9
     [Google Scholar]
  88. 88. 
    Basile C, Della-Morte D, Cacciatore F et al. 2014. Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopenia. Exp. Gerontol. 58:43–46
     [Google Scholar]
  89. 89. 
    Goodpaster BH, Park SW, Harris TB et al. 2006. The loss of skeletal muscle strength, mass, and quality in older adults: the Health, Aging and Body Composition Study. J. Gerontol. A 61:1059–64
     [Google Scholar]
  90. 90. 
    Muto Y, Sato S, Watanabe A et al. 2005. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol. 3:705–13
     [Google Scholar]
  91. 91. 
    Targher G, Bertolini L, Rodella S et al. 2007. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30:2119–21
     [Google Scholar]
  92. 92. 
    Fargion S, Porzio M, Fracanzani AL. 2014. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J. Gastroenterol. 20:13306–24
     [Google Scholar]
  93. 93. 
    Younossi ZM, Koenig AB, Abdelatif D et al. 2016. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84
     [Google Scholar]
  94. 94. 
    Tana C, Ballestri S, Ricci F et al. 2019. Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int. J. Environ. Res. Public Health 16:3104
     [Google Scholar]
  95. 95. 
    Targher G, Byrne CD, Lonardo A et al. 2016. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J. Hepatol. 65:589–600
     [Google Scholar]
  96. 96. 
    Targher G, Byrne CD, Tilg H. 2020. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69:1691–705
     [Google Scholar]
  97. 97. 
    Long MT, Zhang X, Xu H et al. 2021. Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the Framingham Heart Study. Hepatology 73:548–59
     [Google Scholar]
  98. 98. 
    Janičko M, Veselíny E, Leško D, Jarčuška P. 2013. Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. Ann. Hepatol. 12:581–87
     [Google Scholar]
  99. 99. 
    Lee JI, Kim MC, Moon BS et al. 2016. The relationship between 10-year cardiovascular risk calculated using the pooled cohort equation and the severity of non-alcoholic fatty liver disease. Endocrinol. Metab. 31:86–92
     [Google Scholar]
  100. 100. 
    Athyros VG, Boutari C, Stavropoulos K et al. 2018. Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Curr. Vasc. Pharmacol. 16:246–53
     [Google Scholar]
  101. 101. 
    Bader T. 2010. The myth of statin-induced hepatotoxicity. Am. J. Gastroenterol. 105:978–80
     [Google Scholar]
  102. 102. 
    Björnsson ES. 2017. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 37:173–78
     [Google Scholar]
  103. 103. 
    Kaplan DE, Serper MA, Mehta R et al. 2019. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology 156:1693–706.e12
     [Google Scholar]
  104. 104. 
    Dongiovanni P, Petta S, Mannisto V et al. 2015. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol. 63:705–12
     [Google Scholar]
  105. 105. 
    Nascimbeni F, Aron-Wisnewsky J, Pais R et al. 2016. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 3:e000075
     [Google Scholar]
  106. 106. 
    Cholankeril G, Patel R, Khurana S, Satapathy SK. 2017. Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management. World J. Hepatol. 9:533–43
     [Google Scholar]
  107. 107. 
    Yang HI, Yuen MF, Chan HL et al. 2011. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 12:568–74
     [Google Scholar]
  108. 108. 
    Esfeh JM, Hajifathalian K, Ansari-Gilani K. 2020. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin. Mol. Hepatol. 26:54–59
     [Google Scholar]
  109. 109. 
    Simmons O, Fetzer DT, Yokoo T et al. 2017. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment. Pharmacol. Ther. 45:169–77
     [Google Scholar]
  110. 110. 
    EASL (Eur. Assoc. Study Liver) 2018. EASL clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 69:182–236
     [Google Scholar]
  111. 111. 
    Marrero JA, Kulik LM, Sirlin CB et al. 2018. Diagnosis, staging, and manag. ement of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–50
     [Google Scholar]
  112. 112. 
    Honap S, Oben JA. 2021. Fat and hidden liver cancer. Clin. Liver Dis. 17:49–52
     [Google Scholar]
  113. 113. 
    Chernyak V, Fowler KJ, Kamaya A et al. 2018. Liver Imaging Reporting And Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–30
     [Google Scholar]
  114. 114. 
    Gawrieh S, Dakhoul L, Miller E et al. 2019. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment. Pharmacol. Ther. 50:809–21
     [Google Scholar]
  115. 115. 
    Ahmed OT, Allen AM 2019. Extrahepatic malignancies in nonalcoholic fatty liver disease. Curr. Hepatol. Rep. 18:455–72
     [Google Scholar]
/content/journals/10.1146/annurev-med-042220-020407
Loading
Fatty Liver Disease: Diagnosis and Stratification
Annual Review of Medicine 73, 529 (2022); https://doi.org/10.1146/annurev-med-042220-020407
/content/journals/10.1146/annurev-med-042220-020407
/content/journals/10.1146/annurev-med-042220-020407
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error